Innospec (NASDAQ:IOSP – Get Free Report) is expected to be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $1.12 per share and revenue of $443.00 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 10:00 AM ET.
Innospec (NASDAQ:IOSP – Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.09. Innospec had a return on equity of 10.89% and a net margin of 1.08%.The business had revenue of $439.70 million during the quarter, compared to the consensus estimate of $440.70 million. During the same period in the previous year, the business earned $1.39 EPS. The business’s quarterly revenue was up 1.1% on a year-over-year basis. On average, analysts expect Innospec to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Innospec Trading Up 0.7%
Shares of NASDAQ IOSP opened at $73.58 on Monday. Innospec has a twelve month low of $72.03 and a twelve month high of $128.35. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 94.33 and a beta of 1.04. The business has a 50 day simple moving average of $79.52 and a 200-day simple moving average of $83.70.
Analyst Ratings Changes
View Our Latest Stock Report on Innospec
Institutional Investors Weigh In On Innospec
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC raised its stake in shares of Innospec by 8,176.5% in the 1st quarter. Millennium Management LLC now owns 170,414 shares of the specialty chemicals company’s stock valued at $16,147,000 after acquiring an additional 168,355 shares in the last quarter. Qube Research & Technologies Ltd increased its position in shares of Innospec by 72.1% during the second quarter. Qube Research & Technologies Ltd now owns 306,761 shares of the specialty chemicals company’s stock valued at $25,796,000 after purchasing an additional 128,544 shares during the period. Jane Street Group LLC increased its position in shares of Innospec by 1,551.5% during the first quarter. Jane Street Group LLC now owns 95,243 shares of the specialty chemicals company’s stock valued at $9,024,000 after purchasing an additional 89,476 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Innospec by 68.0% during the second quarter. Cubist Systematic Strategies LLC now owns 219,088 shares of the specialty chemicals company’s stock valued at $18,423,000 after purchasing an additional 88,661 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Innospec by 403.0% in the 2nd quarter. AQR Capital Management LLC now owns 72,024 shares of the specialty chemicals company’s stock valued at $6,057,000 after buying an additional 57,706 shares in the last quarter. 96.64% of the stock is owned by hedge funds and other institutional investors.
About Innospec
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.
Recommended Stories
- Five stocks we like better than Innospec
- How to Invest in Insurance Companies: A Guide
- Is Lemonade Stock Set for a Big Squeeze After Earnings?
- What is the FTSE 100 index?
- Caterpillar Stock Could Top $650 by Year’s End
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- ServiceNow’s 5-for-1 Split Is a Signal for Investors to Buy
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.
